Veeva and IQVIA Unveil Global Clinical Partnership as Trading Volume Surges 52.22% to 259th Rank

Veeva Systems (VEEV) closed 0.53% higher on August 18, 2025, with a trading volume of $350 million, marking a 52.22% surge from the prior day and ranking 259th in market activity. The move followed a significant strategic development: Veeva and IQVIA announced a long-term global partnership to integrate their clinical and commercial capabilities, resolving all pending legal disputes. The collaboration enables customers to combine Veeva’s software with IQVIA’s data, technology, and analytics in key areas such as master data management, analytics, and clinical trial execution. Veeva CEO Peter Gassner emphasized the potential for “significant value” through streamlined integration, while IQVIA’s Ari Bousbib highlighted accelerated clinical development and improved patient access to treatments.

Under the agreement, IQVIA joins Veeva’s CRO Clinical Data Partner program, allowing the use of Veeva’s Clinical Suite—including EDC tools—for trial execution. Commercially, the firms established master data and third-party access agreements, enabling cross-platform interoperability for analytics and AI applications. These partnerships aim to reduce operational friction for joint customers, with IQVIA also joining Veeva’s Technology, AI, and Services Partner Programs to enhance integration. The resolution of legal disputes further removes potential barriers to collaboration, positioning both firms to expand their combined market reach in the life sciences sector.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to the present delivered a compound annual growth rate of 6.98%, with a maximum drawdown of 15.46% recorded during the backtest period. The approach showed steady growth over time, though a notable decline in mid-2023 underscores the need for risk management in high-volume trading strategies.